Navigation Links
MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
Date:1/30/2008

GERMANTOWN, Md., Jan. 30 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that it has closed its previously announced private placement of common stock and warrants, resulting in the receipt of $21 million in gross proceeds.

The Company intends to use the proceeds from the financing to support the manufacture of MOXATAG(TM), its once-daily amoxicillin product, and for working capital and general corporate purposes.

The shares sold in the private placement and the shares issuable upon the exercise of the related warrants have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States without being registered with the Securities and Exchange Commission ("SEC") or through an applicable exemption from SEC registration requirements. The shares and warrants were offered and sold only to institutional and accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the common stock issued in the private placement and issuable upon the exercise of the warrants.

This news release is not an offer to sell or the solicitation of an offer to buy the shares of the Company.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercial
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Access Pharmaceuticals Announces $2.7 Million New Equity
3. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
4. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
5. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
6. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
7. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
8. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
9. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
10. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
11. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... STOCKHOLM, September 4 Karolinska Development (publ),today ... has,concluded an extensive clinical study of its candidate drug, ... labor during childbirth.,The promising results of the Phase II ... Karolinska Development,s business strategy. , ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a ... that BioSpecifics, President, Tom Wegman, will present at the upcoming ... 10, 2009, at 12:05pm ET at the New York Palace ... A live webcast of the presentation can be accessed ...
... , , , , SAN ... the Company will present at the following investor conferences: , , ... 2:45 p.m. Eastern Time (ET) on September 9. , Thomas ... , The 2009 Morgan Stanley Global Healthcare Unplugged Conference in ...
Cached Biology Technology:Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 2Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 3Gen-Probe to Webcast Four Upcoming Investor Presentations 2
(Date:4/22/2014)... There are all sorts of signaling strategies in nature. ... tails; satin bowbirds build specialized stick structures, called bowers, ... European bitterling males show off bright nuptial coloration during ... to communicate with others. , ... profound fitness implications for individuals that are either signaling ...
(Date:4/22/2014)... must be aware of the broad patent landscape and ... a new paper from Rice University,s Baker Institute for ... the journal Regenerative Medicine , the paper is ... in the case Association for Molecular Pathology (AMP) v. ... court case and rulings garnered discussion in the public ...
(Date:4/22/2014)... have presented Beaumont Health System with prestigious, competitive ... both athletic and nonathletic injuries. , The ... $40,000 grant to fund stem cell-based research that ... a ruptured knee anterior cruciate ligament, or ACL. ... anterior cruciate ligament injury is the over-stretching or ...
Breaking Biology News(10 mins):Best practices in communication for the animal world 2Best practices in communication for the animal world 3New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3Beaumont awarded grants to study sports-related injury treatment, improve recovery 2
... Patients with symptomatic moderate asthma who were treated ... antibody, experienced significantly fewer disease exacerbations than individuals ... the first issue for October 2006 of the ... published by the American Thoracic Society. , Trevor ...
... harnessing of 'T-rays' - electromagnetic terahertz waves - which ... varied as biological cell abnormalities and explosives has been announced. ... in Spain have said they have found a way to ... Their findings are set out in a letter published in ...
... theories regarding consciousness, emotion and quality of life ... (ALS, also known as 'Lou Gerhig's disease') are ... interaction. ALS is a progressive disease that destroys ... latest issue of Psychophysiology. The article reviews the ...
Cached Biology News:Monoclonal antibody reduces exacerbations in asthmatics 2T-ray breakthrough could make detecting disease far easier 2Computer with brain connections changing quality of life of paralyzed 2
Glutamate Receptor 5/1a...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Dog polyclonal to Porcine Pancreatic Islets of Langerhans Cells ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Pig): Sonicated crude membrane fraction of porcine p...
Biology Products: